Wissenschaft & Forschung
Priv. Doz. Dr. Igor Vujic ist Dermatologe und Forscher. Derzeit arbeitet er als Oberarzt in der KA Rudolfstiftung (Leitung Prof. Rappersberger) und als Wahlarzt für Dermatologie in 1030 Wien.
Seine engsten wissenschaftlichen Mitarbeiter sind Dr. Martina Sanlorenzo, Dr. Marin Vujic, Dr. Christian Posch und Prof. Klemens Rappersberger. Dazu kommen viele ausgezeichnete Kollegen aus Italien, Österreich und den USA und hervorragende junge Studenten und Diplomanden die allesamt den wissenschaftlichen Drang verspüren und die eine oder andere wissenschaftliche Frage bereits beantworten konnten.
Derzeitige wissenschaftlichen Interessen von Dr. Vujic betreffen vor Allem entzündliche Hauterkrankungen wie die Psorasis und den oralen Lichen ruber planus und den schwarzen Hautkrebs, das Melanom.
Unten finden Sie eine Auflistung von laufenden Forschungsprojekten und bereits publizierten Arbeiten. Aktuelle Publikationen sowie weitere Meßgrößen des wissenschaftlichen Outputes finden sie bitte hier.
Falls sie nähere Fragen zur Forschung und Wissenschaft haben bitte kontaktieren Sie uns unter
Auswahl an wissenschaftlichen Publikationen, laufenden Studien, Vorträgen und Forschungsgeldern:
Priv. Doz. Dr. Igor Vujic – Preise/Grants/Forschungsgelder
(Stand 03/2018)
LEO Foundation grant, Principal Investigator, DKK 265.000; Project: “Serum transcriptomics in melanoma patients”, Oct 2016-current
Future Leaders in Dermatology, Scholarship, Madrid, Spain, 2016
Imrich Sarkany Memorial-Scholarship, European Academy of Dermatology and Venereology, Copenhagen, DENMARK, 2015
Austrian Dermatology Prize – “UNILEVER Preis”, Vienna, Austria, 2015
Priv. Doz. Dr. Igor Vujic – Auswahl an Vorlesungen, Vorträgen und Poster
(Stand 03/2018)
‘Lehrveranstatung Diagnose und Therapie komplizierter dermatologischer Krankheitsbilder’ Freifach, LV-Nr. 722005, MUW, 2017SS; Vienna, Austria
‘Block 18 2017SS (Studium der Human Medizin) und Block Z1 2017WS (Studium der Zahnmedizin)’ Externer Vortragender; Vienna, Austria
‘Erkrankungen der Mundschleimhaut und Gesichtshaut von Apthen bis zum Zoster’ Fortbildung des Zahnärztlichen Interessenverbandes; 24 January 2018; Vienna, Austria (invited speaker)
‘Melanom - aktueller Stand der Immuntherapie’ 17. Onkologische Wintergespräche; 12-13 January 2018; Vienna, Austria (invited speaker)
‘Melanom – skin cancer’ Best of Dermatology; 20-21 October 2017; Vienna, Austria (invited speaker)
‘Apremilast in der Psoriasis - Real-World Daten für die Praxis’ 5. Wiener Dermatologie Tag; 7 October 2017; Vienna, Austria (invited speaker)
‘Schnitzler syndrome’; 26th EADV Congress; Geneva, 23-17 September 2017 (invited speaker)
‘Hyperactive NRAS downstream signaling induces specific transcriptome changes –esiRNA based identification of new therapeutic targets in NRAS mutant melanoma identifies the noncoding RNA 7SL as a major proliferation enhancer’ Austrian Society of Dermatology and Venerology Meeting; 25-28 Nov. 2016;Vienna, Austria (oral presentation)
‘Hyperactive NRAS downstream signaling induces specific transcriptome changes –esiRNA based identification of new therapeutic targets in NRAS mutant melanoma identifies the noncoding RNA 7SL as a major proliferation enhancer’ Future leaders of Dermatology Meeting; 10-12 Nov. 2016; Madrid, Spain (oral presentation)
‘Fluorescence-Advanced-Videodermatoscopy (FAV): a new method for in-vivo skin evaluation’ Austrian Society of Dermatology and Venerology Meeting; 25-28 Nov. 2016; Vienna, Austria (oral presentation)
‘Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells’ Austrian Society of Dermatology and Venerology Meeting; 4 – 6. December 2016; Vienna, Austria (oral presentation)
‘Pitfalls in the diagnosis of atopic dermatitis’, 25th EADV Congress; 28.Sep – 2.Oct. 2016; Vienna, Austria, (invited speaker)
‘Schnitzler syndrome‘; 24th EADV Congress; 9-12 October 2015; Copenhagen, Denmark (invited speaker)
‘Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer’, Austrian Society of Dermatology and Venerology Meeting; 24-26 November 2014, Vienna, Austria (oral presentation)
‘Anti-PD1 treatment: cutaneous adverse events and correlation with disease progression’. Austrian Society of Dermatology and Venerology Meeting; 21-23 November 2014; Vienna, Austria (poster)
‘Novel long-non-coding RNA in melanoma: MIRAT a biomarker of MEK inhibitor response’. 2015 Keystone Symposia Conference- Long Noncoding RNAs: From Evolution to Function; 15-20 March 2015; Keystone, Colorado, USA (poster)
‘Pembrolizumab treatment: Cutaneous adverse events and correlation with disease progression’. 2015 SID Annual Meeting; 6-9 May 2015; Atlanta, USA (poster)
Priv. Doz. Dr. Igor Vujic – Aktuelle Studien und abgeschlossene Diplomarbeiten und SSM3 Projekte (MUW)
(Stand 03/2018)
‘Ciclosporin A in oral lichen planus – a prospective cohort study’ Diplomarbeit; cand. med. Christina Ellersdorfer
‘Lingua geographica in psoriasis patients’ Diplomarbeit; cand. med. Sofia Grabovac
‘Ustekinumab, Ixekizumab and brodalumab in real world psoriasis patients’ SSM3 Projekt (Med. Uni. Wien) und darausfolgende Diplomarbeit; cand. med. Elina Gugenheimer
‘LncRna als Biomarker im Plasma von PatientInnen mit malignem Melanom - eine Pilotstudie’. Dr. med. Theresa Böhm, 2017
‘Patterns of metastatic spread in sentinel lymph node negative melanomas’. Dr. med. Anna Stöberl, 2016
Priv. Doz. Dr. Igor Vujic – Laufende Studien mit Externen Institutionen
(Stand 07/2020)
‘Which lncRNA in NRAS mutant melanoma are important for cell survival?’ Univeristy of California San Fransico, Ortiz lab.
‘Tumor infiltrating lymphocytes and peptide treatment’. IMBA Wien, Dr. Josef Penninger.
Project IPSZ Biobank IMBA – Rudolfstiftung. IMBA Wien, Dr. Josef Penninger, Dr. Chukwuma Allison Agu
Role of plasmocytoid dendritic cells in melanoma tumors. Comprehensive Cancer Center Vienna. Prof. Maria Sibilia, Dr. Martina Sanlorenzo.
Priv. Doz. Dr. Igor Vujic – Publikationsliste
(Stand 27.03.2018)
Auswahl an publizierten Originalarbeiten in Journalen mit „peer – review System“
(* contributed equally)
Sanlorenzo M*, Vujic I*, Esteve-Puig R*, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. Jul 2018
Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibillia M, Carnevale-Schianca F, Aglietta M, Sangiolo D. BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody. Clin cancer res. Accepted March 2018.
Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter. Apremilast in psoriasis - a prospective real-world study. J Eur Acad Dermatol Venereol. 2018 Feb;32(2):254-259. doi: 10.1111/jdv.14598. Epub 2017 Oct 12.
Sanlorenzo M, Vujic I, De Giorgi V, Tomasini C, Deboli T, Quaglino P, Fierro MT, Broganelli P. Fluorescence-advanced videodermatoscopy: a new method for in vivo skin evaluation. Br J Dermatol. 2017 Nov;177(5):e209-e210.
Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients. J Am Acad Dermatol. 2017 Jul;77(1):123-129.e5. doi: 10.1016/j.jaad.2017.01.055. Epub 2017 Apr 1
Sanlorenzo M, Vujic I, Carnevale-Schianca F, Quaglino P, Gammaitoni L, Fierro MT, Aglietta M, Sangiolo D. Role of interferon in melanoma: old hopes and new perspectives. Expert Opin Biol Ther. 2017 Apr;17(4):475-483. doi: 10.1080/14712598.2017.1289169. Epub 2017 Feb 16. Review. Erratum in: Expert Opin Biol Ther. 2018 Mar;18(3):1
Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget. 2016 Jul 19;7(29):45916-45925. doi: 10.18632/oncotarget.10001. PubMed PMID: 27322141; PubMed Central PMCID: PMC5216770.
Dapavo P*, Vujic I*, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Oct;75(4):736-739. doi: 10.1016/j.jaad.2016.04.068. Epub 2016 Jul26.
Kwong A, Sanlorenzo M, Rappersberger K, Vujic I. Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. Wien Med Wochenschr. 2017 Jan 13.
Richter L*, Vujic I*, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger K. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317.
Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells. J Invest Dermatol. 2016 Oct;136(10):2041-2048.
Sanlorenzo M, Vujic I, Posch C, Ma J, Lin K, Lai K, Lee D, Vujic M, Oses-Prieto JA, Chand S, Rodriguez-Peralto JL, Burlingame A, Ortiz-Urda S. Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J Proteomics. 2016 Jul 20;144:140-7
Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K, Ortiz-Urda S. Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol. 2016 Jul;136(7):1330-1336. doi: 10.1016/j.jid.2016.03.006. Epub 2016 May 7.
Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, Ortiz-Urda S, Posch C, Feichtinger H, Hackl M, Rappersberger K. The burden of malignant melanoma-lessons to be learned from Austria. Eur J Cancer. 2016 Mar;56:45-53.
Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy R, Moy A, Posch C, Monshi B, Rappersberger K, Ortiz-Urda S. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.
Sanlorenzo M, Vujic I, Ortiz-Urda S. Time-Dependent Measurement of Adverse Events-Reply. JAMA Dermatol. 2015 Dec 1;151(12):1392-1393.
Stöllberger C, Vujic I, Wollmann E, Freudenthaler J, Finsterer J. Carvajal syndrome with oligodontia, hypoacusis, recurrent infections, and noncompaction. Int J Cardiol. 2016 Jan 15;203:825-7.
Vigl K, Monshi B, Vujic I, Rappersberger K. Pyoderma gangrenosum-like necrotizing panniculitis associated with alpha-1 antitrypsin deficiency: a lethal course. J Dtsch Dermatol Ges. 2015 Nov;13(11):1180-4.
Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S. Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox. Clin Cosmet Investig Dermatol. 2015 Aug 5;8:423-9. doi: 10.2147/CCID.S87645. eCollection 2015. Review.
Sanlorenzo M*, Vujic I*, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov;151(11):1206-1212.
Sanlorenzo M, Vujic I, Moy A, Quaglino P, Fierro MT, Gammaitoni L, Carnevale-Schianca F, Aglietta M, Sangiolo D. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. Expert Opin Biol Ther. 2015;15(10):1491-500.
Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz/Urda S. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol. 2015 Oct;135(10):2475-2483. doi: 10.1038/jid.2015.198. Epub 2015 May 27.
Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015 Apr 20;10(4):e0126988. doi: 10.1371/journal.pone.0126988. eCollection 2015.
Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes. JAMA Dermatol. 2015 Apr;151(4):450-2. doi: 10.1001/jamadermatol.2014.4643.
Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20;6(2):969-78.
Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16.
Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014 Sep 15;5(17):7936-44.
Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014 Sep 8;9(9):e107255. doi: 10.1371/journal.pone.0107255. eCollection 2014.
Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE, Ortiz-Urda S. The risk of melanoma in airline pilots and cabin crew: a meta-analysis. JAMA Dermatol. 2015 Jan;151(1):51-8. doi: 10.1001/jamadermatol.2014.1077.
Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza Á, Ortiz-Urda S. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices. 2015 Feb;17(1):15.
Vujic I, Marker M, Posch C, Mühlehner D, Monshi B, Breier F, Steiner A, Ortiz-Urda S, Rappersberger K. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):542-8. doi: 10.1111/jdv.12626. Epub 2014 Aug 4.
Monshi B, Posch C, Vujic I, Sesti A, Sobotka S, Rappersberger K. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients. J Am Acad Dermatol. 2014 Oct;71(4):738-44. doi: 10.1016/j.jaad.2014.05.039. Epub 2014 Jul 9.
Latorre A, Posch C, Garcimartín Y, Celli A, Sanlorenzo M, Vujic I, Ma J, Zekhtser M, Rappersberger K, Ortiz-Urda S, Somoza Á. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale. 2014 Jul 7;6(13):7436-42.
Vujic I, Shroff A, Grzelka M, Posch C, Monshi B, Sanlorenzo M, Ortiz-Urda S, Rappersberger K. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):595-8. doi: 10.1111/jdv.12392. Epub 2014 Feb 17.
Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Melanoma immunotherapy. Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20. Review.
Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18;110(6):1427-32.
Vujic I, Richter L, Bartsch K, Monshi B, Rappersberger K. Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonists. Eur J Dermatol. 2013 Nov-Dec;23(6):895-6.
